{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:58Z","timestamp":1791575398142,"version":"4.3.4"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune-related pancreatitis is a rare but clinically significant adverse event associated with immune checkpoint inhibitor therapy. Early recognition and appropriate management are essential to prevent potentially serious outcomes. Herein, we report a case of suspected immune-related pancreatitis during nivolumab-based immunotherapy for metastatic gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>An 82-year-old female patient, post-gastrectomy for gastric cancer with subsequent cerebral metastases, multiple leptomeningeal metastases, subcutaneous metastases, and retroperitoneal lymph node metastases, received \u201cnivolumab\u2005+\u2005apatinib\u201d therapy for 4 cycles. On the second day of the fourth cycle of treatment, the patient developed mild epigastric pain, acid regurgitation, and elevated pancreatic enzyme levels, suggestive of immune-related pancreatitis. Alternative etiologies, including biliary disease, alcohol use, and hypertriglyceridemia, were excluded. The patient was classified as Grade 1 according to the Common Terminology Criteria for Adverse Events v5.0 and was managed with fasting, parenteral nutrition, octreotide, enzyme inhibition, and electrolyte balance adjustment. Pancreatic enzyme levels normalized, and symptoms resolved. Nivolumab and apatinib were subsequently withheld.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case highlights that immune-related pancreatitis may present with only mild abdominal symptoms despite marked pancreatic enzyme elevation during immune checkpoint inhibitor therapy. Clinicians should maintain a high index of suspicion for pancreatic immune-related adverse events, even in the absence of typical imaging findings, and systematically exclude alternative causes to ensure timely and appropriate management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050285","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:38Z","timestamp":1791572498000},"page":"e50285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of a case of immune-related pancreatitis induced by anti-PD-1 antibody therapy for gastric cancer"],"prefix":"10.1097","volume":"105","author":[{"given":"Fengyun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, North China Electric Power University Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7947-2999","authenticated-orcid":false,"given":"Wenhua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fourth Medical Center of the PLA General Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis.","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"1166299","DOI":"10.3389\/fimmu.2023.1166299","article-title":"Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019.","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-3-030-79308-1_13","article-title":"Hepatobiliary and pancreatic adverse events.","volume":"1342","author":"Zhang","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"1243773","DOI":"10.3389\/fimmu.2023.1243773","article-title":"Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review.","volume":"14","author":"Fang","year":"2023","journal-title":"Front Immunol"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","article-title":"Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment.","volume":"25","author":"Hsu","year":"2020","journal-title":"Oncologist"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/MPA.0000000000001107","article-title":"Anti-PD-1 drug (nivolumab) may induce acute and life-threatening pancreatitis in lung cancer patient.","volume":"47","author":"Jiang","year":"2018","journal-title":"Pancreas"},{"key":"R10-20261009","first-page":"A167","article-title":"5PSQ-039 pancreatitis induced by immunotherapy? Two case reports.","volume":"27","author":"Dom\u00ednguez Bachiller","year":"2020","journal-title":"Eur J Hosp Pharmacy"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2018.02.006","article-title":"Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?","volume":"95","author":"Capurso","year":"2018","journal-title":"Eur J Cancer"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"208","DOI":"10.36401\/JIPO-21-11","article-title":"Case report: nivolumab-induced autoimmune pancreatitis.","volume":"4","author":"Goyal","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:40Z","timestamp":1791572500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050285"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":13,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050285","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2025-10-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}